Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Gastric Cancer Clinical Trial

Official title:

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04555304
• Other study ID #: KH903-40101-CRP
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 15, 2020
• Est. completion date: January 15, 2022

Study information

• Verified date: September 2020
• Source: Chengdu Kanghong Biotech Co., Ltd.
• Contact: yi ba, PhD
• Phone: 13752157916
• Email: bayi[@]timuch.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of the study drug known as KH903 in participants with gastric and gastroesophageal cance

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 81
• Est. completion date: January 15, 2022
• Est. primary completion date: January 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1.Prior to any detailed procedures of this study, subjects are able to understand, voluntarily participate in and sign the informed consent approved by the ethics committee.

• 2.Age = 18 years.

• 3.Histologically confirmed, unresectable, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma .

• 4.Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.

• 5.Have experienced documented objective radiographic or symptomatic disease progression during first-line therapy, or within 4 months after the last dose of first-line therapy with any platinum or/and fluoropyrimidine doublet for unresectable or metastatic disease.Second line chemotherapy is suitable for paclitaxel.

• 6.Laboratory test values must meet the following criteria. ANC =1.5×109/L, platelets = 100×109/L, hemoglobin=9g/dL. Blood creatinine = 1.5 ×ULN or creatinine clearance = 50 mL/min/m2. Total bilirubin = 1.5× ULN(= 3 x ULN if Gilbert disease), AST and ALT = 2.5× ULN (= 5×ULN if hepatic metastasis).

INR = 1.5× ULN, APTT = 1.5× ULN. Dipstick proteinuria <2+ or 24 hour proteinuria <1g .

• 7.Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1.

• 8.Life expectancy of = 3 months.

Exclusion Criteria:

• 1.Histologically confirmed squamous cell carcinoma or undifferentiated gastric cancer.

• 2.Patients with disease progression within 6 months after previous adjuvant or neoadjuvant chemotherapy with paclitaxel, or patients with recurrent or metastatic gastric adenocarcinoma or GEJ adenocarcinoma treated with paclitaxel.

• 3. GI perforation and/or fistulae in the 6 months preceding randomization.

• 4.Deep-vein thrombosis, pulmonary embolism (PE), or any other episode of Uncontrolled thromboembolism in the 6 months preceding randomization.

• 5.Any arterial thromboembolic event (such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack)

• 6.Uncontrolled hypertension (=150/100 mm Hg ) despite properly observed antihypertensive therapy.

• 7.Known brain metastasis.

• 8.Known allergy to paclitaxel or KH903.

• 9.Serious concurrent infection or medical illness.

• 10.Active hepatitis B virus or Active hepatitis C virus (HCV) infection at screening.

• 11.Any condition which results in an undue risk for the patient during the trial participation according to the investigator.

Related Conditions & MeSH terms

• Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Cancer

Intervention

Drug:
• KH903 + Paclitaxel
KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle; Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
• Placebo + Paclitaxel
Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle; Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chengdu Kanghong Biotech Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival(PFS)	Date of randomization until the date of first documented Progression or date of death from any cause, whichever came first	Time from date of randomization until the date of first documented Progression or date of death from any cause, whichever came frist,assessed up to18 months
Secondary	Objective Response Rate (ORR)	Percentage of Participants with a Best Overall Response (BOR) of Partial Response (PR) or Complete Response (CR)	Time from date of randomization until the date of first documented CR or PR,assessed up to18 months
Secondary	Duration of Response (DOR)	is defined as the time from first documented evidence of CR or PR until the date of first documented progression as assessed by RECIST 1.1 or death; assessed up to18 months	Time from first documented evidence of CR or PR until the date of first documented progression ,assessed up to18 months
Secondary	Disease Control Rate (DCR)	Percentage of Participants who have achieved CR, PR and SD to study treatment;	Time from date of randomization until the date of first documented Progression,assessed up to18 months
Secondary	AE	Number of Subjects with treatment-related adverse events (AEs)Defined by all	AEs(NCI CTCAE 5.0) collected at each cycle,Assessed up to18 months